Ritchie Karen, Ritchie Craig W, Yaffe Kristine, Skoog Ingmar, Scarmeas Nikolaos
Institut National de la Santé et de la Recherche Médicale, U1061 Neuropsychiatry, Montpellier, France.
Faculty of Medicine, University of Montpellier, France.
Alzheimers Dement (N Y). 2015 Jul 26;1(2):122-130. doi: 10.1016/j.trci.2015.06.004. eCollection 2015 Sep.
Increasing evidence suggests that Alzheimer's disease (AD) may begin decades before evidence of dementia, indicating that it may be a disorder of midlife rather than old age.
In the absence of long-term prospective studies from early adulthood specifically designed to address this question, a group of international experts examined evidence presently available from previous clinical and population studies to provide an evidence-based opinion as to whether such a change in conceptualization may be justified.
Although still lacking confirmation from dedicated prospective biomarker studies, there is already considerable evidence to suggest both risk factor exposure and brain changes may be already present in midlife.
Current evidence suggests (1) that a change in clinical approach notably involving promotion of cardiovascular health in persons with a family history of AD may considerably reduce disease risk and (2) that the development of biomarkers at this early stage will lead to the possibility of clinical trials at a much earlier stage.
越来越多的证据表明,阿尔茨海默病(AD)可能在出现痴呆症状的数十年前就已开始,这表明它可能是一种中年疾病而非老年疾病。
由于缺乏专门针对此问题从成年早期开始的长期前瞻性研究,一组国际专家审查了先前临床和人群研究中现有的证据,以便就是否有理由进行这种概念上的转变提供基于证据的意见。
尽管仍缺乏专门的前瞻性生物标志物研究的证实,但已有大量证据表明,中年时可能已经存在风险因素暴露和大脑变化。
目前的证据表明:(1)临床方法的改变,特别是在有AD家族史的人群中促进心血管健康,可能会显著降低疾病风险;(2)在这一早期阶段开发生物标志物将使更早阶段进行临床试验成为可能。